EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Multiple Sclerosis and Lung Cancer: A Single Cancer Center Experience in Philadelphia

Julia Palecki, Matthew Tucker, Andrew Bernstein, Garrett Melby, Tingting Zhan, Ida Micaily

Clinical Lung Cancer · 2025

DOI: 10.1016/j.cllc.2025.04.013 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lung Cancer, 2025. Verfasst von Julia Palecki und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Thomas Jefferson University, Philadelphia, PA. Hauptthemen laut MEDLINE: Lung Neoplasms, Multiple Sclerosis, Carcinoma, Non-Small-Cell Lung. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The association between multiple sclerosis (MS) and lung cancer (LC) remains poorly understood. This retrospective, single center study aims to characterize the clinical features and outcomes of LC in patients with MS, shedding light on this unique patient cohort characterized by immune dysregulation and significant immunosuppressive therapy. METHODS: This retrospective study analyzed 38 MS patients diagnosed with LC at Sidney Kimmel Comprehensive Cancer Center at Jefferson in Philadelphia, PA between January 1, 2016 and July 1, 2023. Clinical data including patient demographics, MS treatments, cancer diagnosis details (date, stage, histology), molecular and fusion data, PD-L1 status, and survival data were recorded and analyzed. RESULTS: In our cohort of 38 patients, 27 patients were female. Twenty nine patients identified as White and 6 as Black. About 33 patients had NSCLC (24 adenocarcinoma, 6 squamous cell carcinoma, 1 large cell lung cancer, 1 mucoepidermoid tumor, and 1 carcinoid tumor), 3 had SCLC, and 1 had unknown pathology. Nine patients received steroids and 15 received biologic therapy for the treatment of MS. The median time between MS and LC diagnosis was 16.3 years. The average age at LC diagnosis was 68.2 ± 9.8 years. Among the 38 patients, 19 patients were diagnosed with stage I disease, 2 were diagnosed with stage II, 1 was diagnosed with stage III, and 16 were diagnosed with stage IV diseases. Among 15 patients with molecular testing, BRAF mutation was found in 1 patient, EGFR mutation in 4 patients, and KRAS mutation in 2 patients. 1 patient out of 14 tested demonstrated an ALK fusion. PD-L1 testing was recorded in 12 patients: 3 had 0%, 6 had 1% to 49%, and 3 had > 50% PD-L1 expression. The average overall survival was 2.4 years (95% CI: 1.4-8.1 years). CONCLUSIONS: Patients with MS were significantly exposed to immunosuppressive therapies, which may impact immune surveillance and the development of LC. In this cohort, MS patients with LC exhibited targetable mutations and PD-L1 expression. However, the use of immunotherapy in LC with concurrent MS remains limited. Nearly half of the patients had stage I LC and demonstrated favorable overall survival. Our findings highlight the need for further investigation into the relationship between MS and LC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsMultiple SclerosisCarcinoma, Non-Small-Cell LungHumansFemaleMaleRetrospective StudiesMiddle AgedAgedPhiladelphiaAdultMutationFollow-Up StudiesPrognosisSurvival Rate

Stichwörter der Autor:innen

AutoimmuneImmune dysregulationImmune surveillanceImmunotherapyNSCLC

Autor:innen und Institutionen

  • Department of Internal Medicine, Thomas Jefferson University, Philadelphia, PA.
  • Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA.
  • Sidney Kimmel Comprehensive Cancer Center, Thomas Jefferson University, Philadelphia, PA. Electronic address: ida.micaily@jefferson.edu.

Zitieren

APA

Palecki, J., Tucker, M., Bernstein, A., Melby, G., Zhan, T., & Micaily, I. (2025). Multiple Sclerosis and Lung Cancer: A Single Cancer Center Experience in Philadelphia. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2025.04.013

Vancouver

Palecki J, Tucker M, Bernstein A, Melby G, Zhan T, Micaily I. Multiple Sclerosis and Lung Cancer: A Single Cancer Center Experience in Philadelphia. Clinical Lung Cancer. 2025. doi:10.1016/j.cllc.2025.04.013

BibTeX
@article{Palecki2025,
  author = {Palecki, Julia and Tucker, Matthew and Bernstein, Andrew and Melby, Garrett and Zhan, Tingting and Micaily, Ida},
  title = {Multiple Sclerosis and Lung Cancer: A Single Cancer Center Experience in Philadelphia},
  journal = {Clinical Lung Cancer},
  year = {2025},
  doi = {10.1016/j.cllc.2025.04.013}
}
Kostenlos starten →